Drugs / A2B543
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06051695 | Apr 2024 → Jun 2028 expected | colon carcinoma, colorectal adenocarcinoma, malignant mesothelioma, malignant pancreatic neoplasm +3 | A2 Biotherapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | A2 Biotherapeutics Inc. | Regulatory A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster a2bio.com ↗ |
| 2026-01-08 | A2 Biotherapeutics Inc. | Regulatory A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression a2bio.com ↗
FDA clearance of our IND for A2B543 is an important milestone for A2 Bio. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2B543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06051695 ↗ |
| Modality | Cell therapy | “Autologous logic-gated Tmod CAR T cells” NCT06051695 ↗ |
| Route | Intravenous | “single dose of A2B543 intravenously on day 0” NCT06051695 ↗ |
| Target | MSLN | “Tmod CAR T-cell therapy will enable the killing of tumor target cells (those cells that express MSLN” NCT06051695 ↗ |